Adrenocortical Carcinoma Treatment Market Research Report – Forecast to 2027

Adrenocortical Carcinoma Treatment Market Research Report: By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2027

ID: MRFR/Pharma/5105-HCR | February 2021 | Region: Global | 100 pages

Adrenocortical Carcinoma Treatment Market Scenario


The adrenocortical carcinoma treatment market is expected to grow steadily over the forecast period. It is estimated that the adrenocortical carcinoma treatment market is expected to register a CAGR ~ 2.6 % with an anticipated market value of USD 678 million during the forecast period from 2018 to 2023.


Adrenocortical carcinoma is cancer that arises from the adrenal cortex, which is the outer layer of the adrenal gland. It is rare and aggressive in form, and the management requires a multidisciplinary approach. Numerous factors such as an increase in prevalence rates of rare cancers and the increased focus of companies on the treatment of adrenocortical carcinomas are expected to drive the growth of the market. Thus, there is an increase in the number of drugs in clinical trials for specific chemotherapeutics. According to the Journal of Clinical Endocrinology & Metabolism, the incidence of adrenocortical carcinoma ranges between 40-50 years, whereas women are 55–60% more likely to get affected with a ratio of 1.5:1. In April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification, and mutations. ARQ 087 is a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor.


However, the discrimination of benign from malignant adrenocortical carcinoma requires the evaluation of multiple parameters. Additionally, the pathohistological diagnosis remains challenging. According to a journal published by the National Center for Biotechnology Information, the rate of incorrect initial histopathological diagnosis in Germany was 13% in the year 2016. Therefore, the lack of skilled oncology experts to derive special diagnostic algorithms remains a prominent restraint for the growth of the market. Moreover, the high risk of local recurrence and metastatic progression also hampers the growth of this market.


Segmentation


The adrenocortical carcinoma treatment market has been segmented into type, therapy, and end-user.


The market, on the basis of type, has been segmented into localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.


The localized adrenocortical carcinoma segment is estimated to hold the largest share as it is the most common type with a high occurrence rate. The metastatic adrenocortical carcinoma segment is projected to be the fastest growing owing to increased occurrence rate.


The market, by therapy, has been segmented into surgery, chemotherapy, targeted therapy, radiation therapy, adjuvant therapy, and others.


The market, based on surgery, has been further segmented into laparoscopic surgery and open surgery.


The market, on the basis of radiation therapy, has been sub-segmented into external beam radiation therapy and brachytherapy.


The market, on the basis of end-user, has been segmented into hospitals and clinics, ambulatory surgical centers, and cancer research institutes.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The adrenocortical carcinoma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European adrenocortical carcinoma treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The adrenocortical carcinoma treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The adrenocortical carcinoma treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd., Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation are some of the key players in the global adrenocortical carcinoma treatment market.


Regional Market Summary


Adrenocortical Carcinoma Treatment Market Share (%), by Region, 2017


Adrenocortical Carcinoma Treatment Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the adrenocortical carcinoma treatment market owing to a well-developed healthcare sector and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region contributes to the growth of the market. According to United States Surveillance Epidemiology and End Results (SEER) program, it is estimated that there are 19 to 20 new cases of adrenocortical carcinoma per year in children and adolescents in the US.


Europe is expected to hold the second largest position in the adrenocortical carcinoma treatment market. The market growth in this region owes to the availability of funds for research and increasing healthcare expenditure.


Asia-Pacific is predicted to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East & Africa is expected to have the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to growing government initiatives for the healthcare sector.


Adrenocortical Carcinoma Treatment Market, by Type



  • Localized Adrenocortical Carcinoma

  • Metastatic Adrenocortical Carcinoma


Adrenocortical Carcinoma Treatment Market, by Therapy



  • Surgery

  • Laparoscopic surgery

  • Open surgery

  • Chemotherapy

  • Targeted Therapy

  • Radiation Therapy

  • External beam radiation therapy

  • Brachytherapy

  • Adjuvant Therapy

  • Others


Adrenocortical Carcinoma Treatment Market, by End-User



  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Cancer Research Institutes


Adrenocortical Carcinoma Treatment Market, by Region



  • Americas





    • North America

    • US

    • Canada

    • South America





  • Europe





    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe





  • Asia-Pacific





    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa





    • Middle East

    • Africa




Intended Audience



  • Pharmaceutical companies

  • Oncology research institutes

  • Research and Development (R&D) companies

  • Diagnostic laboratories

  • Government research institutes

  • Academic institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 678 Million
  • 2027: Significant Value
  •   CAGR   2.6% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Therapy, and End-user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. Ltd. Hitachi Ltd. NeuroLogica Corp., and Digirad Corporation
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increase in prevalence rates of rare cancers
  • Increased focus of companies on the treatment of adrenocortical carcinomas


  • Frequently Asked Questions (FAQ) :


    The CAGR for Adrenocortical Carcinoma Treatment market would be 2.6% during the forecast period.

    Lack of oncology experts and high risk of local occurrence and different metastatic progress can deter Adrenocortical Carcinoma Treatment market growth.

    The types included in Adrenocortical Carcinoma Treatment market report are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.

    The Americas would dominate the Adrenocortical Carcinoma Treatment market.

    The APAC region would dominate Adrenocortical Carcinoma Treatment market in terms of growth rate.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Adrenocortical Carcinoma Treatment Market, by Type

    6.1 Introduction

    6.2 Localized Adrenocortical Carcinoma

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Metastatic Adrenocortical Carcinoma

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Adrenocortical Carcinoma Treatment Market, by Therapy

    7.1 Introduction

    7.2 Surgery

    7.2.1 Laparoscopic surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.2 Open surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Chemotherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Targeted Therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Radiation Therapy

    7.5.1 External beam radiation therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5.2 Brachytherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.6 Adjuvant Therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.7 Others

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Adrenocortical Carcinoma Treatment Market, by End-User

    8.1 Introduction

    8.2 Hospitals and Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Ambulatory Surgical Centers

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Cancer Research Institutes

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 9. Global Adrenocortical Carcinoma Treatment, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 South Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11. Company Profiles

    11.1 Arqule

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Pfizer Ltd.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 EnGeneIC Ltd

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Exelixis, Inc.

    11.4.1 Company Overview

    11.4.2 Product Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Millendo Therapeutics, Inc.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Merck & Co.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Orphagen Pharmaceuticals, Inc.

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 HRA Pharma

    11.8.1 Overview

    11.8.2 Product Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Bristol-Myers Squibb Company

    11.9.1 Overview

    11.9.2 Product Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 General Electric Company

    11.10.1 Overview

    11.10.2 Product Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 WG Critical Care, LLC

    11.11.1 Overview

    11.11.2 Product Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Mylan N.V.

    11.12.1 Overview

    11.12.2 Product Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Fresenius Kabi AG

    11.13.1 Overview

    11.13.2 Product Overview

    11.13.3 Financials

    11.13.4 Key Developments

    11.13.5 SWOT Analysis

    11.14 SINOVISION Technologies (Beijing)CO., Ltd.

    11.14.1 Overview

    11.14.2 Product Overview

    11.14.3 Financials

    11.14.4 Key Developments

    11.14.5 SWOT Analysis

    11.15 Hitachi, Ltd.

    11.15.1 Overview

    11.15.2 Product Overview

    11.15.3 Financials

    11.15.4 Key Developments

    11.15.5 SWOT Analysis

    11.16 NeuroLogica Corp.

    11.16.1 Overview

    11.16.2 Product Overview

    11.16.3 Financials

    11.16.4 Key Developments

    11.16.5 SWOT Analysis

    11.17 Digirad Corporation

    11.17.1 Overview

    11.17.2 Product Overview

    11.17.3 Financials

    11.17.4 Key Developments

    11.17.5 SWOT Analysis

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s Viewpoint

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Predictions for the Adrenocortical Carcinoma Treatment Industry

    Chapter 13. Appendix


    LIST OF TABLES

    Table 1 Global Adrenocortical Carcinoma Treatment Market Synopsis, 2020–2027

    Table 2 Global Adrenocortical Carcinoma Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 4 Global Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 5 Global Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 6 Global Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027(USD Million)

    Table 7 North America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 8 North America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 9 North America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 10 North America: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 11 US: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 12 US: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 13 US: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 14 US: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 15 Canada: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 16 Canada: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 17 Canada: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 18 Canada: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 19 South America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 20 South America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 21 South America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 22 South America: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 23 Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 24 Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 25 Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 26 Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 27 Western Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 28 Western Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 29 Western Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 30 Western Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 31 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 32 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 33 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 33 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 34 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 35 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 36 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

    Table 37 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

    Table 38 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 39 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Adrenocortical Carcinoma Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Adrenocortical Carcinoma Treatment Market

    Figure 4 Global Adrenocortical Carcinoma Treatment Market Share, by Type, 2020 (%)

    Figure 5 Global Adrenocortical Carcinoma Treatment Market Share, by Therapy, 2020 (%)

    Figure 6 Global Adrenocortical Carcinoma Treatment Market Share, by End-User, 2020 (%)

    Figure 7 Global Adrenocortical Carcinoma Treatment Market Share, by Region, 2020 (%)

    Figure 8 North America: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

    Figure 9 Europe: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

    Figure 10 Asia-Pacific: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

    Figure 11 Middle East & Africa: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

    Figure 12 Global Adrenocortical Carcinoma Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 Arqule: Key Financials

    Figure 14 Arqule: Segmental Revenue

    Figure 15 Arqule: Geographical Revenue

    Figure 16 Pfizer Ltd.: Key Financials

    Figure 17 Pfizer Ltd.: Segmental Revenue

    Figure 18 Pfizer Ltd.: Geographical Revenue

    Figure 19 EnGeneIC Ltd: Key Financials

    Figure 20 EnGeneIC Ltd: Segmental Revenue

    Figure 21 EnGeneIC Ltd: Geographical Revenue

    Figure 22 Exelixis, Inc.: Key Financials

    Figure 23 Exelixis, Inc.: Segmental Revenue

    Figure 24 Exelixis, Inc.: Geographical Revenue

    Figure 25 Millendo Therapeutics, Inc.: Key Financials

    Figure 26 Millendo Therapeutics, Inc.: Segmental Revenue

    Figure 27 Millendo Therapeutics, Inc.: Geographical Revenue

    Figure 28 Merck & Co.: Key Financials

    Figure 29 Merck & Co.: Segmental Revenue

    Figure 30 Merck & Co.: Geographical Revenue

    Figure 31 Orphagen Pharmaceuticals, Inc.: Key Financials

    Figure 32 Orphagen Pharmaceuticals, Inc.: Segmental Revenue

    Figure 33 Orphagen Pharmaceuticals, Inc.: Geographical Revenue

    Figure 34 HRA Pharma: Key Financials

    Figure 35 HRA Pharma: Segmental Revenue

    Figure 36 HRA Pharma: Geographical Revenue

    Figure 37 Bristol-Myers Squibb Company: Key Financials

    Figure 38 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 39 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 40 General Electric Company: Key Financials

    Figure 41 General Electric Company: Segmental Revenue

    Figure 42 General Electric Company: Geographical Revenue

    Figure 43 WG Critical Care, LLC: Key Financials

    Figure 44 WG Critical Care, LLC: Segmental Revenue

    Figure 45 WG Critical Care, LLC: Geographical Revenue

    Figure 46 Mylan N.V.: Key Financials

    Figure 47 Mylan N.V.: Segmental Revenue

    Figure 48 Mylan N.V.: Geographical Revenue

    Figure 49 Fresenius Kabi AG: Key Financials

    Figure 50 Fresenius Kabi AG: Segmental Revenue

    Figure 51 Fresenius Kabi AG: Geographical Revenue

    Figure 52 SINOVISION Technologies (Beijing)CO.,Ltd.: Key Financials

    Figure 53 SINOVISION Technologies (Beijing)CO.,Ltd.: Segmental Revenue

    Figure 54 SINOVISION Technologies (Beijing)CO.,Ltd.: Geographical Revenue

    Figure 55 Hitachi, Ltd.: Key Financials

    Figure 56 Hitachi, Ltd.: Segmental Revenue

    Figure 57 Hitachi, Ltd.: Geographical Revenue

    Figure 58 NeuroLogica Corp.: Key Financials

    Figure 59 NeuroLogica Corp.: Segmental Revenue

    Figure 60 NeuroLogica Corp.: Geographical Revenue

    Figure 61 Digirad Corporation: Key Financials

    Figure 62 Digirad Corporation: Segmental Revenue

    Figure 63 Digirad Corporation: Geographical Revenue